Impax Laboratories Inc
Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
Teva’s Recent Launch of Generic Solodyn: What You Need to Know
On February 20, 2018, Teva Pharmaceutical announced the US launch of the generic version of Solodyn Extended Release tablets in two strengths.
How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017
In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.
Depomed versus Peers in March 2018: Analyst Ratings
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions.
A Look at AbbVie’s Neuroscience Portfolio
In 2016, AbbVie’s (ABBV) Duodopa, a combination drug for the treatment of advanced Parkinson’s disease, generated revenue of ~$293 million.
Mylan’s EpiPen Controversy: Is It a Brand or a Generic?
Mylan has been embroiled in a controversy over whether its EpiPen is classified as a generic or a branded product and whether its 500.0% price hike is justified.
Why Mylan’s Specialty Segment Reported Strong Q1 Growth
The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.
Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial
On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.
Generic Companies Are Fighting for Market Share
The generic pharmaceutical industry is characterized by low concentration. The top ten global generic companies hold less than 50% of the market share.
Is a Para IV Filing Rewarding for a Generic Company?
A generic company is rewarded for a Para IV filing. The first applicant to submit a substantially completed ANDA is given marketing exclusivity for 180 days.
Regulations Are Instrumental in the Marketing Authorization Process
To overcome the issues of the costly and time consuming marketing authorization process, the Hatch-Waxman Act introduced the ANDA process to make approvals efficient.
Why Is the Generics Industry Controlled by Regulations?
The generics pharmaceutical industry is highly regulated. The drug approval process and the regulatory bodies governing them differ from market to market.
What Two Factors Are Driving the US Generics Market?
The US generics industry is fragmented. The top five companies accounted for 44.4% of the market share of unbranded generics in 2013, according to IMS Health.
What’s Supporting Continued Growth in the Generics Market?
The global generics market was valued at $168 billion in 2013. From 2013 to 2018, it’s expected to grow at a CAGR of 11% to reach $283 billion.
Why the Generic Industry’s Classification Is Still Evolving
The generics industry primarily caters to several large diseases in primary care. Healthcare is organized into three categories—primary, secondary, and tertiary.
Are Generics the Only Affordable Drugs?
Drugs are used to treat, cure, or prevent diseases. The drug market is broadly categorized into prescription drugs and OTC (over-the-counter) drugs.
What Investors Need to Know about Branded and Generic Drugs
The prescription drug market is divided into two categories—branded or generic drugs. Branded drugs are patented drugs. Generics are off-patented drugs.